Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia argyi extract
- Development stage
- Phase 3
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
CKD-495 (Esogreen) is a botanical drug developed by Chong Kun Dang for the treatment of acute and chronic gastritis. It is a 95% ethanol soft extract derived from *Artemisia argyi* Herba (Aeyeop). The drug exerts its therapeutic effects through gastric mucosal protection, including the stimulation of endogenous prostaglandin synthesis (specifically PGE2), scavenging of reactive oxygen species, and inhibition of inflammatory mediators such as TNF-alpha and NF-kappaB. It was developed as an incrementally modified drug (IMD) in South Korea, offering improved stability or manufacturing processes compared to existing Artemisia-based treatments. CKD-495 received approval from the South Korean Ministry of Food and Drug Safety (MFDS) in 2022 for the improvement of gastric mucosal lesions (erosion, hemorrhage, redness, edema) associated with gastritis.
- Brand names
- Esogreen
- Other names
- Artemisia argyi Herba 95% ethanol soft extract에소그린
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))NF-κBALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Artemisia argyi extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artemisia argyi extract.